{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T11:03:24Z","timestamp":1781348604310,"version":"3.54.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC) in \u223c30% of all infected individuals. Here, we present a case of PASC in a patient with rheumatoid arthritis characterized by viral persistence in the nasopharynx for 6 months after acute infection. We demonstrate transient disappearance of antigen persistence and decreased antiviral and autoimmune T cell responses after nirmatrelvir\/ritonavir and tocilizumab treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 37-year-old female with a 7-year history of rheumatoid arthritis enrolled in a COVID-19 research study was found to continuously test SARS-CoV-2 antigen positive in the nasopharynx for 6 months after acute infection. She simultaneously presented with new-onset PASC symptoms including chronic occipital headache and periods of intense fatigue 8 weeks after acute infection. The patient was prescribed nirmatrelvir\/ritonavir to treat SARS-CoV-2 persistence at 3.5 months post-acute infection and observed a reduction in PASC symptoms 3 weeks after completing antiviral treatment. After resurgence of PASC symptoms, she stopped treatment with tocilizumab for rheumatoid arthritis to attempt complete SARS-CoV-2 viral clearance. The severity of the patient\u2019s PASC symptoms subsequently increased, and she developed new-onset brain fog in addition to previous symptoms, which resolved after resumption of tocilizumab treatment. Assessment of adaptive immune responses demonstrated that nirmatrelvir\/ritonavir and tocilizumab treatment decreased antiviral and autoreactive T cell activation. After resuming tocilizumab treatment, the patient\u2019s PASC symptoms were significantly reduced, but nasopharyngeal antigen positivity remained.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These data suggest that nirmatrelvir\/ritonavir should be considered in the treatment of PASC in patients who have SARS-CoV-2 antigen persistence, though care must be taken to monitor the patient for symptom resurgence or viral reactivation. In addition, the IL-6 inhibitor tocilizumab may ameliorate PASC symptoms in patients with persistent headache, fatigue, and brain fog.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.1003103","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T09:27:50Z","timestamp":1663925270000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence"],"prefix":"10.3389","volume":"9","author":[{"given":"Lavanya","family":"Visvabharathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Orban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor J.","family":"Koralnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"B1","year":"2021","journal-title":"Cumulative Worldwide Covid-19 Cases."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/acn3.51350","article-title":"Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 \u201clong haulers\u201d.","volume":"8","author":"Graham","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/10408363.2020.1860895","article-title":"COVID-19: From an acute to chronic disease? Potential long-term health consequences.","volume":"58","author":"Higgins","year":"2020","journal-title":"Crit Rev Clin Lab Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41564-022-01163-3","article-title":"Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2.","volume":"7","author":"Newman","year":"2022","journal-title":"Nat Microbiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1186\/s12913-020-06001-y","article-title":"Persistent symptoms after Covid-19: qualitative study of 114 \u201clong Covid\u201d patients and draft quality principles for services.","volume":"20","author":"Ladds","year":"2020","journal-title":"BMC Health Serv Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11910-021-01130-1","article-title":"The Neurological manifestations of post-acute sequelae of SARS-CoV-2 infection.","volume":"21","author":"Moghimi","year":"2021","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome.","volume":"27","author":"Nalbandian","year":"2021","journal-title":"Nat Med."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01267-y","article-title":"Therapeutic Approaches to the Neurologic Manifestations of COVID-19.","author":"Graham","year":"2022","journal-title":"Neurotherapeutics."},{"key":"B9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.4049\/jimmunol.1600320","article-title":"Cytokine-independent detection of antigen-specific germinal center t follicular helper cells in immunized nonhuman primates using a live cell activation-induced marker technique.","volume":"197","author":"Havenar-Daughton","year":"2016","journal-title":"J Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1093\/cid\/ciab408","article-title":"Population-based estimates of post-acute sequelae of SARS-CoV-2 infection (PASC) prevalence and characteristics.","volume":"73","author":"Hirschtick","year":"2021","journal-title":"Clin Infect Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1001\/jama.2021.5612","article-title":"Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers.","volume":"325","author":"Havervall","year":"2021","journal-title":"JAMA."},{"key":"B12","first-page":"jrm00063","article-title":"Long-term clinical outcomes in survivors of severe acute respiratory syndrome and middle east respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis.","volume":"52","author":"Ahmed","year":"2020","journal-title":"J Rehabil Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3390\/curroncol28010083","article-title":"Prolonged SARS-CoV-2-RNA detection from nasopharyngeal swabs in an oncologic patient: What impact on cancer treatment?","volume":"28","author":"Ferrari","year":"2021","journal-title":"Curr Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.medj.2022.04.001","article-title":"Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection.","volume":"3","author":"Natarajan","year":"2022","journal-title":"Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13756-022-01067-1","article-title":"Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values.","volume":"11","author":"Thornton","year":"2022","journal-title":"Antimicrob Resist Infect Control."},{"key":"B16","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00134-021-06416-z","article-title":"Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.","volume":"47","author":"Snow","year":"2021","journal-title":"Intensive Care Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19a meta-analysis.","volume":"54","author":"Wen","year":"2022","journal-title":"Ann Med."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac512","article-title":"Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19.","author":"Boucau","year":"2022","journal-title":"Clin Infect Dis."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1101\/2022.06.21.22276724","article-title":"COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022.","author":"Wang","year":"2022","journal-title":"medRxiv"},{"key":"B20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41590-021-01113-x","article-title":"Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection.","volume":"23","author":"Phetsouphanh","year":"2022","journal-title":"Nat Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"105295","DOI":"10.1016\/j.psyneuen.2021.105295","article-title":"Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19.","volume":"131","author":"Kappelmann","year":"2021","journal-title":"Psychoneuroendocrinology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.medj.2021.03.013","article-title":"Alterations in T and B cell function persist in convalescent COVID-19 patients.","volume":"2","author":"Shuwa","year":"2021","journal-title":"Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S2213-2600(22)00127-8","article-title":"Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study.","volume":"10","author":"Evans","year":"2022","journal-title":"Lancet Respir Med."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.08.21261763","article-title":"Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and responses to vaccination.","author":"Visvabharathy","year":"2021","journal-title":"medRxiv"},{"key":"B25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","article-title":"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.","volume":"52","author":"Listing","year":"2013","journal-title":"Rheumatology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/ard.60.1.49","article-title":"Recognition of YKL-39, a human cartilage related protein, as a target antigen in patients with rheumatoid arthritis.","volume":"60","author":"Sekine","year":"2001","journal-title":"Ann Rheum Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/s41591-022-01840-0","article-title":"Long COVID after breakthrough SARS-CoV-2 infection.","volume":"28","author":"Al-Aly","year":"2022","journal-title":"Nat Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jama.2022.11691","article-title":"Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers.","volume":"328","author":"Azzolini","year":"2022","journal-title":"JAMA."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1003103\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T09:27:52Z","timestamp":1663925272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1003103\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":28,"alternative-id":["10.3389\/fmed.2022.1003103"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1003103","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"article-number":"1003103"}}